Articles
How to Navigate the Biosimilar and Biologic Markets Amid Challenging US Litigation Trends
Intellectual Asset Management
By Gerard P. Norton, Jonathan R. Lagarenne, Jianming Jimmy Hao, Howard S. Suh and Jonathan J. Madara
Publications
Articles
What's Next for Hatch-Waxman Litigation and Improper Orange Book Patent Listings?
New Jersey Law Journal
By Peter J. Butch III and Howard S. Suh
Articles
Biosimilars and Biologics Litigation in the United States
IAM
By Gerard P. Norton, Ph.D., Jonathan R. Lagarenne, Jianming Jimmy Hao, Ph.D., Howard S. Suh and Jonathan J. Madara
Alerts
USPTO Post-Grant Proceedings: An Overview
By Howard Suh
Illumina v. Ariosa: Carving Out a New 'Bucket' of Section 101 Patent Eligible Claims
By Howard S. Suh
